Summary
The cytokine IL-6 plays a central role in maintaining chronic inflammation in rheumatoid arthritis (RA). Tocilizumab is the first humanized interleukin-6 receptor inhibiting monoclonal antibody and represents a novel mechanism of action to treat RA. This article presents data from the phase 3 Tocilizumab Pivotal Trial in Methotrexate Inadequate Responders [OPTION] international study, involving 623 patients with moderate to severe RA.
- © 2007 MD Conference Express
Tools
Tocilizumab, a Novel Monoclonal Antibody Targeting IL-6 Signaling, Significantly Reduces Disease Activity in Patients with Rheumatoid Arthritis
Permalink:
Table of contents
Cited By...
- No citing articles found.